Michael Castagna, PharmD, MBA, has significant sales and marketing experience, but does he have enough time or money to rescue Afrezza?
MannKind Corp., the maker of the inhaled insulin Afrezza, on Monday named a veteran chief commercial officer, but not all industry-watchers were convinced the company is poised for the powerful relaunch that will be needed to make its product a success.
Michael Castagna, PharmD, MBA, will join MannKind after 3 years at Amgen as a vice president and global commercial lead for a portfolio of biosimilar drugs. He was previously at Bristol Myers Squibb as executive director of its immunology franchise, and has also spent time at Sandoz (Novartis), Merck, and other companies.
“I’m very pleased to welcome Michael to the MannKind team in this important new role,” said CEO Matthew Pfeffer. “His extensive pharma background, including driving sales and marketing for so many new and relaunched products, will be invaluable as we prepare to reintroduce Afrezza to the market in the upcoming months.”
MannKind: Path to Afrezza Survival Involves Lower Prices to Woo Payers
Castagna joined the company on the day of a conference call where Pfeffer outlined grim statistics: MannKind finished 2015 with $59.1 million on hand; analysts project it has enough money to last through June.
Though it enjoys a small core of loyal users, the mealtime insulin aimed at giving those with type 1 diabetes (and some with type 2) greater convenience and glycemic control has been a spectacular failure from a sales perspective, causing its marketing partner Sanofi to announce the end of a partnership in January. MannKind regains control of the product April 5, 2016.
Spencer Osborne of Seeking Alpha writes that while Castagna’s background is impressive, the company is running out of time to mount a solid relaunch. “What investors wanted to hear … was that the company was preparing to hit the ground running when Afrezza is fully returned April 5th,” he wrote.
In the new issue of Evidence-Based Diabetes Management, analysts report that MannKind’s survival strategy hinges on overseas markets and cutting prices to gain payer approval. Lack of access to formulary, despite encouraging reports from users who have tried the product, has been a huge barrier to success, in the opinion of the company and some of those who track it.
On Monday, MannKind also announced the resignation of Juergen A. Martens as chief operating officer effective Friday.
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More